IRICoR, Université de Montréal, IRIC and Valence Discovery collaborate to design novel drug candidates for the treatment of levodopa-induced dyskinesia in Parkinson’s disease patients
A leading researcher at Université de Montréal will leverage IRICoR’s expertise in accelerating drug discovery projects and Valence’s AI-enabled platform to design highly selective drug candidates against a newly identified target.
MONTREAL and CAMBRIDGE, Mass., March 10, 2021 – IRICoR, a pan-Canadian drug discovery and research commercialization centre, Université de Montréal (UdeM), the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, and Valence Discovery (“Valence”), an emerging leader in AI-enabled drug design, today announced a collaboration focused on the discovery of novel drug candidates for the treatment of levodopa-induced dyskinesia in Parkinson’s disease.
To read the press release click here